ReviewMolecules (Basel, Switzerland)2026
Saponins Derived from Chinese Medicinal Materials in Hyperuricemia and Gout: Therapeutic Mechanisms and Emerging Perspectives.
Review in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia (HUA) is a metabolic disorder caused by dysregulated uric acid metabolism and constitutes the principal biochemical basis of gout. Persistent elevation of serum uric acid above the saturation threshold promotes monosodium urate crystal deposition in joints, soft tissues, and the kidneys, triggering inflammation and tissue injury. The rising global prevalence of HUA and gout, together with an evident trend toward younger onset, has imposed an increasing public health burden. Traditional Chinese Medicine has been widely used in their management because of its holistic therapeutic approach and favorable safety profile. Among the bioactive constituents derived from Chinese medicinal materials, saponins have attracted particular attention for their multi-target pharmacological actions. Saponin compounds derived from Chinese medicinal materials exert anti-hyperuricemic and anti-gout effects by modulating purine-metabolizing enzymes, regulating urate transporters, restoring gut microbiota homeostasis, and suppressing inflammatory signaling pathways. This review summarizes the pathogenesis of HUA and gout and synthesizes current evidence on the therapeutic mechanisms of saponins derived from Chinese medicinal materials, providing a theoretical basis for the development of novel therapeutic strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.